Juvenile arthritis and autoimmunity to type II collagen

L. K. Myers, G. C. Higgins, T. H. Finkel, A. M. Reed, J. W. Thompson, R. C. Walton, J. Hendrickson, N. C. Kerr, R. K. Pandya-Lipman, B. V. Shlopov, P. Stastny, A. E. Postlethwaite, A. H. Kang

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Objective. Joint inflammation in juvenile rheumatoid arthritis (JRA) is sometimes associated with an autoimmune response to type II collagen (CII), a cartilage-specific protein. To test the hypothesis that down-regulation of autoimmunity to CII can be accomplished in JRA by oral administration of CII, an open-label study of CII was performed in 9 patients with JRA. Methods. Seven rheumatoid factor-negative JRA patients with polyarticular disease and 2 JRA patients with pauciarticular disease (1 with early onset and 1 with late onset) were treated for 3 months with oral bovine CII. Patients were examined for disease activity and underwent routine laboratory testing at monthly intervals. Two of the patients had flares of disease when treatment was discontinued, and these patients were re-treated for an additional 3 months. To test the hypothesis that oral tolerance induces an immune deviation of T cells, peripheral blood mononuclear cells from patients were collected before and after treatment and cultured with CII. Supernatants and RNA were collected and analyzed for the presence of various cytokines. Results. Eight patient trials met the criteria for clinical improvement outlined by Giannini and coworkers in 1997. None of the patients had any side effects from the treatment. In 6 of the 8 patients who improved, interferon-γ production decreased after oral CII therapy, correlating with clinical improvement, while 6 patients had increases in levels of transforming growth factor β3. Conclusion. These results are encouraging. The possible beneficial effect of oral CII in JRA merits further investigation.

Original languageEnglish (US)
Pages (from-to)1775-1781
Number of pages7
JournalArthritis and Rheumatism
Volume44
Issue number8
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Collagen Type II
Juvenile Arthritis
Autoimmunity
Immune Tolerance
Rheumatoid Factor
Transforming Growth Factors
Therapeutics
Interferons
Cartilage
Oral Administration
Blood Cells
Down-Regulation
Joints
RNA
Cytokines
Inflammation
T-Lymphocytes

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Myers, L. K., Higgins, G. C., Finkel, T. H., Reed, A. M., Thompson, J. W., Walton, R. C., ... Kang, A. H. (2001). Juvenile arthritis and autoimmunity to type II collagen. Arthritis and Rheumatism, 44(8), 1775-1781. https://doi.org/10.1002/1529-0131(200108)44:8<1775::AID-ART313>3.0.CO;2-V

Juvenile arthritis and autoimmunity to type II collagen. / Myers, L. K.; Higgins, G. C.; Finkel, T. H.; Reed, A. M.; Thompson, J. W.; Walton, R. C.; Hendrickson, J.; Kerr, N. C.; Pandya-Lipman, R. K.; Shlopov, B. V.; Stastny, P.; Postlethwaite, A. E.; Kang, A. H.

In: Arthritis and Rheumatism, Vol. 44, No. 8, 2001, p. 1775-1781.

Research output: Contribution to journalArticle

Myers, LK, Higgins, GC, Finkel, TH, Reed, AM, Thompson, JW, Walton, RC, Hendrickson, J, Kerr, NC, Pandya-Lipman, RK, Shlopov, BV, Stastny, P, Postlethwaite, AE & Kang, AH 2001, 'Juvenile arthritis and autoimmunity to type II collagen', Arthritis and Rheumatism, vol. 44, no. 8, pp. 1775-1781. https://doi.org/10.1002/1529-0131(200108)44:8<1775::AID-ART313>3.0.CO;2-V
Myers, L. K. ; Higgins, G. C. ; Finkel, T. H. ; Reed, A. M. ; Thompson, J. W. ; Walton, R. C. ; Hendrickson, J. ; Kerr, N. C. ; Pandya-Lipman, R. K. ; Shlopov, B. V. ; Stastny, P. ; Postlethwaite, A. E. ; Kang, A. H. / Juvenile arthritis and autoimmunity to type II collagen. In: Arthritis and Rheumatism. 2001 ; Vol. 44, No. 8. pp. 1775-1781.
@article{a63f3b653028441083a7e377360436a0,
title = "Juvenile arthritis and autoimmunity to type II collagen",
abstract = "Objective. Joint inflammation in juvenile rheumatoid arthritis (JRA) is sometimes associated with an autoimmune response to type II collagen (CII), a cartilage-specific protein. To test the hypothesis that down-regulation of autoimmunity to CII can be accomplished in JRA by oral administration of CII, an open-label study of CII was performed in 9 patients with JRA. Methods. Seven rheumatoid factor-negative JRA patients with polyarticular disease and 2 JRA patients with pauciarticular disease (1 with early onset and 1 with late onset) were treated for 3 months with oral bovine CII. Patients were examined for disease activity and underwent routine laboratory testing at monthly intervals. Two of the patients had flares of disease when treatment was discontinued, and these patients were re-treated for an additional 3 months. To test the hypothesis that oral tolerance induces an immune deviation of T cells, peripheral blood mononuclear cells from patients were collected before and after treatment and cultured with CII. Supernatants and RNA were collected and analyzed for the presence of various cytokines. Results. Eight patient trials met the criteria for clinical improvement outlined by Giannini and coworkers in 1997. None of the patients had any side effects from the treatment. In 6 of the 8 patients who improved, interferon-γ production decreased after oral CII therapy, correlating with clinical improvement, while 6 patients had increases in levels of transforming growth factor β3. Conclusion. These results are encouraging. The possible beneficial effect of oral CII in JRA merits further investigation.",
author = "Myers, {L. K.} and Higgins, {G. C.} and Finkel, {T. H.} and Reed, {A. M.} and Thompson, {J. W.} and Walton, {R. C.} and J. Hendrickson and Kerr, {N. C.} and Pandya-Lipman, {R. K.} and Shlopov, {B. V.} and P. Stastny and Postlethwaite, {A. E.} and Kang, {A. H.}",
year = "2001",
doi = "10.1002/1529-0131(200108)44:8<1775::AID-ART313>3.0.CO;2-V",
language = "English (US)",
volume = "44",
pages = "1775--1781",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "8",

}

TY - JOUR

T1 - Juvenile arthritis and autoimmunity to type II collagen

AU - Myers, L. K.

AU - Higgins, G. C.

AU - Finkel, T. H.

AU - Reed, A. M.

AU - Thompson, J. W.

AU - Walton, R. C.

AU - Hendrickson, J.

AU - Kerr, N. C.

AU - Pandya-Lipman, R. K.

AU - Shlopov, B. V.

AU - Stastny, P.

AU - Postlethwaite, A. E.

AU - Kang, A. H.

PY - 2001

Y1 - 2001

N2 - Objective. Joint inflammation in juvenile rheumatoid arthritis (JRA) is sometimes associated with an autoimmune response to type II collagen (CII), a cartilage-specific protein. To test the hypothesis that down-regulation of autoimmunity to CII can be accomplished in JRA by oral administration of CII, an open-label study of CII was performed in 9 patients with JRA. Methods. Seven rheumatoid factor-negative JRA patients with polyarticular disease and 2 JRA patients with pauciarticular disease (1 with early onset and 1 with late onset) were treated for 3 months with oral bovine CII. Patients were examined for disease activity and underwent routine laboratory testing at monthly intervals. Two of the patients had flares of disease when treatment was discontinued, and these patients were re-treated for an additional 3 months. To test the hypothesis that oral tolerance induces an immune deviation of T cells, peripheral blood mononuclear cells from patients were collected before and after treatment and cultured with CII. Supernatants and RNA were collected and analyzed for the presence of various cytokines. Results. Eight patient trials met the criteria for clinical improvement outlined by Giannini and coworkers in 1997. None of the patients had any side effects from the treatment. In 6 of the 8 patients who improved, interferon-γ production decreased after oral CII therapy, correlating with clinical improvement, while 6 patients had increases in levels of transforming growth factor β3. Conclusion. These results are encouraging. The possible beneficial effect of oral CII in JRA merits further investigation.

AB - Objective. Joint inflammation in juvenile rheumatoid arthritis (JRA) is sometimes associated with an autoimmune response to type II collagen (CII), a cartilage-specific protein. To test the hypothesis that down-regulation of autoimmunity to CII can be accomplished in JRA by oral administration of CII, an open-label study of CII was performed in 9 patients with JRA. Methods. Seven rheumatoid factor-negative JRA patients with polyarticular disease and 2 JRA patients with pauciarticular disease (1 with early onset and 1 with late onset) were treated for 3 months with oral bovine CII. Patients were examined for disease activity and underwent routine laboratory testing at monthly intervals. Two of the patients had flares of disease when treatment was discontinued, and these patients were re-treated for an additional 3 months. To test the hypothesis that oral tolerance induces an immune deviation of T cells, peripheral blood mononuclear cells from patients were collected before and after treatment and cultured with CII. Supernatants and RNA were collected and analyzed for the presence of various cytokines. Results. Eight patient trials met the criteria for clinical improvement outlined by Giannini and coworkers in 1997. None of the patients had any side effects from the treatment. In 6 of the 8 patients who improved, interferon-γ production decreased after oral CII therapy, correlating with clinical improvement, while 6 patients had increases in levels of transforming growth factor β3. Conclusion. These results are encouraging. The possible beneficial effect of oral CII in JRA merits further investigation.

UR - http://www.scopus.com/inward/record.url?scp=0034891060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034891060&partnerID=8YFLogxK

U2 - 10.1002/1529-0131(200108)44:8<1775::AID-ART313>3.0.CO;2-V

DO - 10.1002/1529-0131(200108)44:8<1775::AID-ART313>3.0.CO;2-V

M3 - Article

C2 - 11508428

AN - SCOPUS:0034891060

VL - 44

SP - 1775

EP - 1781

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 8

ER -